SCHEMBL14726808

SCHEMBL14726808

Cc1ccc([C@H]2C[C@@H]2CO)nc1

nearest known ligand 0.49

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 20/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17449566 1.00 PDE10A (0.49) PDE10A
SCHEMBL26124540 1.00 PDE10A (0.49) PDE10A
SCHEMBL26403112 1.00 PDE10A (0.49) PDE10A
SCHEMBL26124537 1.00 PDE10A (0.49) PDE10A
SCHEMBL30608276 1.00 PDE10A (0.49) PDE10A
SCHEMBL30608275 1.00 PDE10A (0.49) PDE10A
SCHEMBL20059879 1.00 PDE10A (0.49) PDE10A
SCHEMBL14726961 0.84 PDE10A (0.50) PDE10A
SCHEMBL20198839 0.83 PDE10A (0.49) PDE10A
SCHEMBL14981999 0.80 PDE10A (0.47) PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214938-A1 PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)-METHANOL MERCK SHARP & DOHME LLC (US) 2025-07-03 US disclosed
US-20250206703-A1 PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL MERCK SHARP & DOHME LLC (US) 2025-06-26 US disclosed
EP-4504703-A1 PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL Merck Sharp & Dohme LLC (US) 2025-02-12 EP disclosed
EP-4504704-A1 PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)-METHANOL Merck Sharp & Dohme LLC (US) 2025-02-12 EP disclosed
WO-2023192178-A1 PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)-METHANOL MERCK SHARP & DOHME LLC (US) 2023-10-05 WO disclosed
WO-2023184486-A1 PROCESS FOR PREPARING ( (1S, 2S) -2- (5-METHYLPYRIDIN-2-YL) CYCLOPROPYL) -METHANOL MERCK SHARP & DOHME LLC (US) 2023-10-05 WO disclosed
WO-2023192170-A1 PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL MERCK SHARP & DOHME LLC (US) 2023-10-05 WO disclosed
WO-2023192170-A1 PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL MERCK SHARP & DOHME LLC (US) 2023-10-05 WO disclosed
WO-2023192178-A1 PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)-METHANOL MERCK SHARP & DOHME LLC (US) 2023-10-05 WO disclosed
EP-2922823-B1 PYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME (US) 2018-10-31 EP disclosed
US-20140336195-A1 ARYLOXMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS MERCK SHARP & DOHME LLC 2014-11-13 US disclosed
WO-2014150114-A1 SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-09-25 WO disclosed
WO-2014139150-A1 SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-09-18 WO disclosed
US-20140228368-A1 PYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME LLC 2014-08-14 US disclosed
US-20140228368-A1 PYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME LLC 2014-08-14 US disclosed
US-20140228368-A1 PYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME LLC 2014-08-14 US disclosed
WO-2014081619-A1 PYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-05-30 WO disclosed
WO-2014081619-A1 PYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-05-30 WO disclosed
WO-2014081617-A1 SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-05-30 WO disclosed
WO-2013028590-A1 PYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228368-A1 PYRIMIDINE PDE10 INHIBITORS PDE12, PDE10A, PDE11A PDE10A 2/4885
US-20250214938-A1 PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)-METHANOL DHPS, CYP2S1, CYP51A1 PDE10A 2799/4885
US-20250206703-A1 PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL ADH1C, ADH1A, CYP2S1 PDE10A 2635/4885
US-20140336195-A1 ARYLOXMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS PDE10A, PDE12, PDE4A PDE10A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.